Selective pharmacological inhibition of phosphoinositide 3-kinase p110delta opposes the progression of autoimmune diabetes in non-obese diabetic (NOD) mice

Autoimmunity

Volumn 46, Issue 1, 2013, Pages 62-73

  Durand, Caylib A ^a   Richer, Martin J ^a   Brenker, Kathrin ^a   Graves, Marcia ^a   Shanina, Iryna ^a   Choi, Kate ^a   Horwitz, Marc S ^a   Puri, Kamal D ^b   Gold, Michael R ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b GILEAD SCIENCES INC   (United States)

Author keywords

IC87114; Marginal zone B cells; NOD mice; Phosphoinositide 3 kinase; Type 1 diabetes

Indexed keywords

GLUCOSE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P110;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTATION; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; B LYMPHOCYTE ACTIVATION; CATALYSIS; CELL EXPANSION; CONTROLLED STUDY; DISEASE COURSE; ENZYME ANALYSIS; ENZYME INHIBITION; FEMALE; GLUCOSE HOMEOSTASIS; IN VITRO STUDY; INCIDENCE; INFLAMMATORY CELL; INSULIN DEPENDENT DIABETES MELLITUS; INTRACELLULAR SIGNALING; LYMPHOCYTE MIGRATION; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; NONOBESE DIABETIC MOUSE; PANCREAS ISLET; PROTEIN EXPRESSION;

ADENINE; ANIMALS; AUTOIMMUNITY; B-LYMPHOCYTES; DIABETES MELLITUS, TYPE 1; DISEASE PROGRESSION; FEMALE; FLOW CYTOMETRY; HISTOCYTOCHEMISTRY; INSULIN-SECRETING CELLS; MICE; MICE, INBRED NOD; MICE, TRANSGENIC; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN KINASE INHIBITORS; QUINAZOLINES; STATISTICS, NONPARAMETRIC;

EID: 84872170692     PISSN: 08916934     EISSN: 1607842X     Source Type: Journal    
DOI: 10.3109/08916934.2012.732130     Document Type: Article

References (61)

1. Cantor, J., and K. Haskins. 2007. Recruitment and activation of macrophages by pathogenic CD4 T cells in type 1 diabetes: Evidence for involvement of CCR8 and CCL1. J. Immunol. 179(9): 5760-5767.
2. Thomas, H. E., R. Darwiche, J. A. Corbett, and T. W. Kay. 2002. Interleukin-1 plus gamma-Interferon-Induced pancreatic beta-cell dysfunction is mediated by beta-cell nitric oxide production. Diabetes 51(2): 311-316. (Pubitemid 34764785)
3. Serreze, D. V., H. D. Chapman, D. S. Varnum, et al. 1996. B lymphocytes are essential for the initiation of T cell-Mediated autoimmune diabetes: Analysis of a new "speed congenic" stock of NOD.Ig mu null mice. J. Exp. Med. 184(5): 2049-2053. (Pubitemid 26404497)
4. Wong, F. S., L.Wen, M. Tang, et al. 2004. Investigation of the role of B-cells in type 1 diabetes in the NOD mouse. Diabetes 53(10): 2581-2587. (Pubitemid 39299265)
5. Tian, J.,D. Zekzer, Y. Lu, H. Dang, andD. L. Kaufman. 2006. B cells are crucial for determinant spreading of T cell autoimmunity among beta cell antigens in diabetes-prone nonobese diabetic mice. J. Immunol. 176(4): 2654-2661. (Pubitemid 43201718)
6. Falcone, M., J. Lee, G. Patstone, B. Yeung, and N. Sarvetnick. 1998. B lymphocytes are crucial antigen-presenting cells in the pathogenic autoimmune response to GAD65 antigen in nonobese diabetic mice. J. Immunol. 161(3): 1163-1168. (Pubitemid 28380541)
7. Marino, E., and S. T. Grey ST. 2008. A new role for an old player: Do B cells unleash the self-Reactive CD8 T cell storm necessary for the development of type 1 diabetes? J. Autoimmun. 31(3): 301-305.
8. Noorchashm, H., Y. K. Lieu, N. Noorchashm, et al. 1999. I-Ag7-Mediated antigen presentation by B lymphocytes is critical in overcoming a checkpoint in T cell tolerance to islet beta cells of nonobese diabetic mice. J. Immunol. 163(2): 743-750. (Pubitemid 29328081)
9. Katz, J. D., B. Wang, K. Haskins, C. Benoist, and D. Mathis. 1993. Following a diabetogenic T cell from genesis through pathogenesis. Cell 74(6): 1089-1100. (Pubitemid 23289465)
10. Brodie, G. M., M. Wallberg, P. Santamaria, F. S. Wong, and E. A. Green. 2008. B-cells promote intra-Islet CD8 cytotoxic T-cell survival to enhance type 1 diabetes. Diabetes 57(4): 909-917.
11. Duan, B., and L. Morel. 2006. Role of B-1a cells in autoimmunity. Autoimmun. Rev. 5(6): 403-408. (Pubitemid 44143033)
12. Pao, L. I., K. P. Lam, J. M. Henderson, et al. 2007. B cellspecific deletion of protein-Tyrosine phosphatase Shp1 promotes B-1a cell development and causes systemic autoimmunity. Immunity 27(1): 35-48. (Pubitemid 47089020)
13. Batten, M., J. Groom, T. G. Cachero, et al. 2000. BAFF mediates survival of peripheral immature B lymphocytes. J. Exp. Med. 192(10): 1453-1466.
14. Marino, E., M. Batten, J. Groom, et al. 2008. Marginal-zone B-cells of nonobese diabetic mice expand with diabetes onset, invade the pancreatic lymph nodes, and present autoantigen to diabetogenic T-cells. Diabetes 57(2): 395-404.
15. Martin, F., and J. F. Kearney. 2002. Marginal-zone B cells. Nat. Rev. Immunol. 2(5): 323-335. (Pubitemid 37328755)
16. Martin, F., A. M. Oliver, and J. F. Kearney. 2001. Marginal zone and B1 B cells unite in the early response against Tindependent blood-borne particulate antigens. Immunity 14(5): 617-629. (Pubitemid 32520872)
17. Lopes-Carvalho, T., and J. F. Kearney. 2004. Development and selection of marginal zone B cells. Immunol. Rev. 197: 192-205. (Pubitemid 38142177)
18. Ryan, G. A., C. J. Wang, J. L. Chamberlain, et al. 2010. B1 cells promote pancreas infiltration by autoreactive T cells. J. Immunol. 185(5): 2800-2807.
19. Noorchashm, H., N. Noorchashm, J. Kern, et al. 1997. B-cells are required for the initiation of insulitis and sialitis in nonobese diabetic mice. Diabetes 46(6): 941-946. (Pubitemid 27220992)
20. Hu, C. Y., D. Rodriguez-pinto, W. Du, et al. 2007. Treatment with CD20-Specific antibody prevents and reverses autoimmune diabetes in mice. J. Clin. Invest. 117(12): 3857-3867. (Pubitemid 350224095)
21. Xiu, Y., C. P. Wong, J. D. Bouaziz, et al. 2008. B lymphocyte depletion by CD20 monoclonal antibody prevents diabetes in nonobese diabetic mice despite isotype-Specific differences in Fc gamma R effector functions. J. Immunol. 180(5): 2863-2875.
22. Fiorina, P., A. Vergani, S. Dada, et al. 2008. Targeting CD22 reprograms B-cells and reverses autoimmune diabetes. Diabetes 57(11): 3013-3024.
23. Zekavat, G., S. Y. Rostami, A. Badkerhanian, et al. 2008. In vivo BLyS/BAFF neutralization ameliorates islet-Directed autoimmunity in nonobese diabetic mice. J. Immunol. 181(11): 8133-8144.
24. Pescovitz, M.D., C. J. Greenbaum, H. Krause-Steinrauf, et al. 2009. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N. Engl. J. Med. 361(22): 2143-2152.
25. Gong, Q., Q. Ou, S. Ye, et al. 2005. Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J. Immunol. 174(2): 817-826. (Pubitemid 40094277)
26. Yu, S., R. Dunn, M. R. Kehry, and H. Braley-Mullen. 2008. B cell depletion inhibits spontaneous autoimmune thyroiditis in NOD.H-2h4 mice. J. Immunol. 180(11): 7706-7713.
27. Okkenhaug, K., and B. Vanhaesebroeck. 2003. PI3K in lymphocyte development, differentiation and activation. Nat. Rev. Immunol. 3(4): 317-330. (Pubitemid 37328684)
28. Okkenhaug, K., and B. Vanhaesebroeck. 2003. PI3Ksignalling in B- And T-cells: Insights from gene-Targeted mice. Biochem. Soc. Trans. 31(PT1): 270-274. (Pubitemid 36241443)
29. Reif, K., K. Okkenhaug, T. Sasaki, et al. 2004. Cutting edge: Differential roles for phosphoinositide 3-kinases, p110g and p110d, in lymphocyte chemotaxis and homing. J. Immunol. 173(4): 2236-2240. (Pubitemid 39063077)
30. Al-Alwan, M. M., K. Okkenhaug, B. Vanhaesebroeck, J. S. Hayflick, and A. J. Marshall. 2007. Requirement for phosphoinositide 3-kinase p110d signaling in B cell antigen receptor-Mediated antigen presentation. J. Immunol. 178(4): 2328-2335. (Pubitemid 46233431)
31. Vanhaesebroeck, B., K. Ali, A. Bilancio, B. Geering, and L. C. Foukas. 2005. Signalling by PI3K isoforms: Insights from gene-Targeted mice. Trends Biochem. Sci. 30(4): 194-204. (Pubitemid 40463309)
32. Bilancio, A., K. Okkenhaug, M. Camps, et al. 2006. Key role of the p110d isoform of PI3K in B-cell antigen and IL-4 receptor signaling: Comparative analysis of genetic and pharmacologic interference with p110d function in B cells. Blood 107(2): 642-650. (Pubitemid 43076389)
33. Jou, S. T., N. Carpino, Y. Takahashi, et al. 2002. Essential, nonredundant role for the phosphoinositide 3-kinase p110d in signaling by the B-cell receptor complex. Mol. Cell Biol. 22(24): 8580-8591. (Pubitemid 35397173)
34. Clayton, E., G. Bardi, S. E. Bell, et al. 2002. A crucial role for the p110d subunit of phosphatidylinositol 3-kinase in B cell development and activation. J. Exp. Med. 196(6): 753-763.
35. Okkenhaug, K., A. Bilancio, G. Farjot, et al. 2002. Impaired B and T cell antigen receptor signaling in p110d PI 3-kinase mutant mice. Science 297(5583): 1031-1034. (Pubitemid 34856039)
36. Sadhu, C., K. Dick, W. T. Tino, and D. E. Staunton. 2003. Selective role of PI3Kd in neutrophil inflammatory responses. Biochem. Biophys. Res. Commun. 308(4): 764-769. (Pubitemid 36976527)
37. Sadhu, C., B. Masinovsky, K. Dick, C. G. Sowell, and D. E. Staunton. 2003. Essential role of phosphoinositide 3-kinase delta in neutrophil directional movement. J. Immunol. 170(5): 2647-2654. (Pubitemid 36245657)
38. Lannutti, B. J., S. A. Meadows, S. E. Herman, et al. 2011. CAL-101, a p110d selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood 117(2): 591-594.
39. Herman, S. E., A. L. Gordon, A. J. Wagner, et al. 2010. Phosphatidylinositol 3-kinase-Delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood 116(12): 2078-2088.
40. Ikeda, H., T. Hideshima, M. Fulciniti, et al. 2010. PI3K/p110d is a novel therapeutic target in multiple myeloma. Blood 116(9): 1460-1468.
41. Lee, K. S., H. K. Lee, J. S. Hayflick, Y. C. Lee, and K. D. Puri. 2006. Inhibition of phosphoinositide 3-kinased attenuates allergic airway inflammation and hyperresponsiveness in murine asthma model. FASEB J. 20(3): 455-465. (Pubitemid 44933322)
42. Puri, K. D., T. A. Doggett, J. Douangpanya, et al. 2004. Mechanisms and implications of phosphoinositide 3-kinase d in promoting neutrophil trafficking into inflamed tissue. Blood 103(9): 3448-3456. (Pubitemid 38525677)
43. Park, S. J., K. S. Lee, S. R. Kim, et al. 2010. Phosphoinositide 3-kinase d inhibitor suppresses interleukin-17 expression in a murine asthma model. Eur. Respir. J. 36(6): 1448-1459.
44. Haylock-Jacobs, S., I. Comerford, M. Bunting, et al. 2011. PI3Kd drives the pathogenesis of experimental autoimmune encephalomyelitis by inhibiting effector T cell apoptosis and promoting Th17 differentiation. J. Autoimmun. 36(3-4): 278-287.
45. Soond, D. R., E. Bjorgo, K. Moltu, et al. 2010. PI3K p110d regulates T-cell cytokine production during primary and secondary immune responses in mice and humans. Blood 115(11): 2203-2213.
46. Marone, R., V. Cmiljanovic, B. Giese, and M. P. Wymann. 2008. Targeting phosphoinositide 3-kinase: Moving towards therapy. Biochim. Biophys. Acta 1784(1): 159-185.
47. Durand, C. A., K. Hartvigsen, L. Fogelstrand, et al. 2009. Phosphoinositide 3-kinase p110d regulates natural antibody production, marginal zone and B-1 B cell function, and autoantibody responses. J. Immunol. 183(9): 5673-5684.
48. Fung-Leung, W. P. 2011. Phosphoinositide 3-kinase d (PI3Kd) in leukocyte signaling and function. Cell Signal. 23(4): 603-608.
49. Ali, K., A. Bilancio,M. Thomas, et al. 2004. Essential role for the p110d phosphoinositide 3-kinase in the allergic response. Nature 431(7011): 1007-1011. (Pubitemid 39434424)
50. Ali, K., M. Camps, W. P. Pearce, et al. 2008. Isoform-Specific functions of phosphoinositide 3-kinases: P110d but not p110g promotes optimal allergic responses in vivo. J. Immunol. 180(4): 2538-2544.
51. Geoffrey, R., S. Jia, A. E. Kwitek, et al. 2006. Evidence of a functional role for mast cells in the development of type 1 diabetes mellitus in the BioBreeding rat. J. Immunol. 177(10): 7275-7286. (Pubitemid 44715097)
52. Okkenhaug, K., D. T. Patton, A. Bilancio, et al. 2006. The p110delta isoform of phosphoinositide 3-kinase controls clonal expansion and differentiation of Th cells. J. Immunol. 177(8): 5122-5128. (Pubitemid 44527583)
53. Sinclair, L. V., D. Finlay, C. Feijoo, et al. 2008. Phosphatidylinositol- 3-OH kinase and nutrient-Sensing mTOR pathways control T lymphocyte trafficking. Nat. Immunol. 9(5): 513-521. (Pubitemid 351560520)
54. Randis, T. M., K. D. Puri, H. Zhou, and T. G. Diacovo. 2008. Role of PI3Kd and PI3Kg in inflammatory arthritis and tissue localization of neutrophils. Eur. J. Immunol. 38(5): 1215-1224.
55. Judkowski, V., C. Pinilla, K. Schroder, et al. 2001. Identification of MHC class II-Restricted peptide ligands, including a glutamic acid decarboxylase 65 sequence, that stimulate diabetogenic T cells from transgenic BDC2.5 nonobese diabetic mice. J. Immunol. 166(2): 908-917. (Pubitemid 32060245)
56. Haskins, K., and M. McDuffie. 1990. Acceleration of diabetes in young NOD mice with a CD4 islet-Specific T cell clone. Science 249(4975): 1433-1436.
57. Mueller, R., L. M. Bradley, T. Krahl, and N. Sarvetnick. 1997. Mechanism underlying counterregulation of autoimmune diabetes by IL-4. Immunity 7(3): 411-418. (Pubitemid 27446015)
58. Michel, C., C. Boitard, and J. F. Bach. 1989. Insulin autoantibodies in non-obese diabetic (NOD) mice. Clin. Exp. Immunol. 75(3): 457-460. (Pubitemid 19109997)
59. von Herrath, M., and G. T. Nepom. 2009. Remodeling rodent models to mimic human type 1 diabetes. Eur. J. Immunol. 39(8): 2049-2054.
60. von Herrath, M., and G. T. Nepom. 2009. Animal models of human type 1 diabetes. Nat. Immunol. 10(2): 129-132.
61. Maxwell, M. J., E. Tsantikos, A. M. Kong, et al. 2012. Attenuation of phosphoinositide 3-kinase delta signaling restrains autoimmune disease. J. Autoimmun. 38(4): 381-391.